Section Arrow
AZTR.NYSE-M
- Azitra
Quotes are at least 15-min delayed:2025/05/29 15:13 EDT
Last
 0.2723
-0.0077 (-2.75%)
Day High 
0.2755 
Prev. Close
0.28 
1-M High
0.3398 
Volume 
315.24K 
Bid
0.2715
Ask
0.2722
Day Low
0.2613 
Open
0.2726 
1-M Low
0.2655 
Market Cap 
4.61M 
Currency USD 
P/E
%Yield -- 
10-SMA 0.28 
20-SMA 0.29 
50-SMA 0.3 
52-W High 12 
52-W Low 0.2325 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
127.00/-0.67
Enterprise Value
4.90M
Balance Sheet
Book Value Per Share
0.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.50K
Operating Revenue Per Share
0.02
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ALZNAlzamend Neuro Inc.5.64+2.32+69.88%-- 
ENTOEntero Therapeutics Inc.0.4255+0.0315+7.99%0.03PE
NCNANuCana plc0.0355-0.002-5.33%-- 
IMNNImunon2.11+0.59+38.82%-- 
NTLAIntellia Therapeutics7.335-2.325-24.07%-- 
Quotes are at least 15-min delayed:2025/05/29 15:13 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.